Piper Sandler began coverage on shares of Monte Rosa Therapeutics (NASDAQ:GLUE) in a report published on Monday, Price Targets.com reports. The firm issued an overweight rating and a $40.00 price objective on the stock. Piper Sandler also issued estimates for Monte Rosa Therapeutics’ Q2 2021 earnings at ($0.47) EPS, Q3 2021 earnings at ($0.38) EPS, Q4 2021 earnings at ($0.41) EPS, FY2021 earnings at ($1.76) EPS, Q1 2022 earnings at ($0.44) EPS, Q2 2022 earnings at ($0.49) EPS, Q3 2022 earnings at ($0.51) EPS, Q4 2022 earnings at ($0.55) EPS and FY2022 earnings at ($1.99) EPS.
GLUE opened at $21.71 on Monday. Monte Rosa Therapeutics has a 1 year low of $18.01 and a 1 year high of $23.77.
About Monte Rosa Therapeutics
Featured Story: Gap Up Stocks
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.